Statistics for Aclaris Therapeutics (id:7920 ACRS)
Valuation metrics
Market cap
308.58M
Enterprise value
157.39M
Trailing P/E (ttm)
-2.99
Forward P/E
-7.45
PEG ratio
-7.45
Price/Sales (ttm)
11.40
Price/Book (mrq)
2.37
Enterprise Value/Revenue
5.81
Enterprise Value/EBITDA
-2.53
Overview
Shares outstanding
71.43M
Float
55.28M
Shares short
2.41M
% Held by insiders
0.03%
% Held by institutions
0.74%
Average volume (10 days)
10.24M
Average volume (90 days)
Price summary
52-Week low
0.77
52-Week high
5.17
52-Week change
77.10%
Beta
0.12
50-Day moving average
1.65
200-Day moving average
1.32
Dividends and splits
Forward annual dividend rate
Forward annual dividend yield
Trailing annual dividend rate
0.00%
Trailing annual dividend yield
0.00
5-Year annual dividend yield
Payout ratio
0.00
Dividend date
Ex-dividend date
Last split factor
2:1
Last split date
Financials
Fiscal yearFiscal year ends
December 31th, 2023
Most recent quarter (mrq)
September 30th, 2024
Profitability
Profit margin
-136.65%
Operating margin
-222.53%
Operational effectiveness
Return on assets
-19.39%
Return on equity
-25.83%
Income statement
Revenue (ttm)
0.38
Revenue per share (ttm)
0.38
Quarterly revenue growth (yoy)
Gross profit (ttm)
13.17M
EBITDA
-62,202,000.00
Net income to common (ttm)
-37,004,000.00
Diluted EPS (ttm)
-0.52
Quarterly earnings growth (yoy)
Balance sheet
Total cash (mrq)
127.72M
Total cash per share (mrq)
1.79
Total debt (mrq)
2.24M
Total Debt/Equity (mrq)
1.72
Current ratio (mrq)
703.30%
Book value per share (mrq)
1.82
Cash flow
Cash flow statement
-17,898,000.00
Levered free cash flow (LFCF)
-22,053,376.00